News in brief - October 2013

Other new launches, licence changes and updates relevant to general practice.

The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment  of type II diabetes.
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment of type II diabetes.
  • Onglyza (saxagliptin) can now be prescribed as monotherapy in type II diabetes inadequately controlled by diet and exercise when metformin is contraindicated or not tolerated.
  • Adults with symptomatic anaemia associated with chronic renal failure being treated with Aranesp (darbepoetin alfa) may now receive once monthly dosing in the correction phase of treatment provided they are not undergoing dialysis.
  • Generic sildenafil tablets are now listed in MIMS for the treatment of erectile dysfunction.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases